KB
BIIB icon

Kimelman & Baird’s Biogen BIIB Stock Holding History

Kimelman & Baird’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,000
Closed -$313K – 118
2016
Q3 		$313K Hold
1,000
– – 0.06% 82
2016
Q2 		$242K Hold
1,000
– – 0.04% 87
2016
Q1 		$260K Hold
1,000
– – 0.05% 96
2015
Q4 		$306K Buy
+1,000
New +$287K 0.06% 88
2015
Q2 		$364K Buy
+900
New +$361K 0.06% 91

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kimelman & Baird's BIIB Position: Q4 2016 in Review

Kimelman & Baird sold out of Biogen (BIIB) in Q4 2016, closing a stake of 1,000 shares — an estimated $313K sold.

Kimelman & Baird first reported a position in BIIB in Q2 2015 and held it in 5 quarters. The position peaked at $364K in Q2 2015. 1,026 funds tracked by Wall St. Rank hold BIIB as of Q4 2016.

  • Kimelman & Baird reported no remaining Biogen position as of Q4 2016 after selling out during the quarter.
  • Kimelman & Baird sold 1,000 Biogen shares in Q4 2016, an estimated $313K.
  • Kimelman & Baird first reported a position in Biogen in Q2 2015 and held it in 5 quarters.
  • Kimelman & Baird's Biogen position peaked at $364K in Q2 2015.
  • 1,026 funds tracked by Wall St. Rank held Biogen as of Q4 2016.

Based on Kimelman & Baird's 13F filing for Q4 2016, filed 10 Apr 2017.